Medication Update: New Pediatric Approval for DUPIXENT® in Chronic Spontaneous Urticaria (CSU)
- In:
Clinical Practice,
Professional Development
DUPIXENT has expanded its support for younger patients with a new pediatric indication for Chronic Spontaneous Urticaria (CSU). The age range for CSU treatment now includes children as young as 2 years old who remain symptomatic despite H1 antihistamine treatment.
For patients aged 2 to 5 years, the recommended weight-based dosing is:
-
5 kg to <15 kg: 200 mg every 4 weeks (Q4W).
-
15 kg to <30 kg: 300 mg every 4 weeks (Q4W).
For the complete prescribing information, click HERE
Elevate-Derm Alliance Editorial Committee